Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

YTTRIUM Y-90 for Radioembolisation: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 9 adverse event reports in the FDA FAERS database where YTTRIUM Y-90 was used for Radioembolisation.

Most Reported Side Effects for YTTRIUM Y-90

Side Effect Reports % Deaths Hosp.
Abdominal pain 17 12.7% 2 13
Off label use 15 11.2% 3 2
Disease progression 14 10.5% 5 1
Drug ineffective 14 10.5% 2 4
Metastases to liver 12 9.0% 9 2
Pyrexia 12 9.0% 1 11
Fatigue 11 8.2% 2 6
Thrombocytopenia 11 8.2% 4 2
Pancreatic carcinoma metastatic 10 7.5% 3 0
Pancreatic neuroendocrine tumour metastatic 9 6.7% 5 0
Vomiting 9 6.7% 1 7
Ascites 8 6.0% 2 7
Diarrhoea 8 6.0% 2 3
Malignant neoplasm progression 8 6.0% 7 0
Pancytopenia 8 6.0% 5 3

Other Indications for YTTRIUM Y-90

Colorectal cancer metastatic (28) Hepatocellular carcinoma (19) Radiotherapy (11) Neuroendocrine tumour (8) Non-hodgkin's lymphoma (8) Pancreatic neuroendocrine tumour metastatic (6) Metastases to liver (5)

Other Drugs Used for Radioembolisation

IODIXANOL (7)

Related Pages

YTTRIUM Y-90 Full Profile All Radioembolisation Drugs YTTRIUM Y-90 Demographics YTTRIUM Y-90 Timeline